论文部分内容阅读
目的观察紫杉醇(PTX)联合奈达铂(NDP)治疗晚期非小细胞肺癌的疗效及不良反应。方法 48例晚期非小细胞肺癌患者应用紫杉醇(PTX)联合奈达铂(NDP)方案化疗:PTX 135~175 mg/m2,静脉滴注,第1天;NDP 80~100 mg/m2,静脉滴注,第2天,21 d为1个周期。结果全组48例患者中,完全缓解率(CR)3例(6.3%),部分缓解率(PR)16例(33.3%),稳定(SD)22例(45.8%),病情进展(PD)7例(14.6%)。有效率(RR)为39.6%,疾病控制率(DCR)为85.4%。主要不良反应为骨髓抑制及胃肠道反应,肝、肾毒性较轻。结论紫杉醇联合奈达铂治疗晚期非小细胞肺癌不良反应轻,疗效较好,值得临床推广。
Objective To observe the efficacy and side effects of paclitaxel (PTX) combined with nedaplatin (NDP) in the treatment of advanced non-small cell lung cancer. Methods Forty-eight patients with advanced non-small cell lung cancer were treated with paclitaxel (PTX) and NDP (cisplatin) chemotherapy: PTX 135-175 mg / m2, intravenous drip on day 1, NDP 80-100 mg / Note, Day 2, 21 d for a cycle. Results Among the 48 patients, complete remission rate (CR) was found in 3 cases (6.3%), partial response rate (PR) in 16 cases (33.3%), stable SD in 22 cases (45.8% 7 cases (14.6%). The effective rate (RR) was 39.6% and the rate of disease control (DCR) was 85.4%. The main adverse reactions are myelosuppression and gastrointestinal reactions, liver, kidney toxicity less. Conclusion paclitaxel combined with nedaplatin treatment of advanced non-small cell lung cancer with mild adverse reactions, the curative effect is good, worthy of clinical promotion.